NouvSight001Beyond's analysis on NouvSight0012026-09-29 — iRegene Therapeutics advances its off‑the‑shelf cell therapy NouvSight001 into clinical trials for retinitis pigmentosa in both the U.S. and ChinaRecent news mentioning NouvSight0012026-09-29 — iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis PigmentosaAppears alongsideChinaBrowse the full archive →